SC
ROIV icon

Stempoint Capital’s Roivant Sciences ROIV Stock Holding History

Stempoint Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-750,000
Closed -$56.3K – 66
2024
Q1 		$56.3K Buy
+750,000
New +$8.09M 0.01% 59

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stempoint Capital's ROIV Position: Q1 2026 in Review

Stempoint Capital reduced its Roivant Sciences (ROIV) stake by 60% in Q1 2026, selling an estimated $14.9M and leaving 385,800 shares worth $10.7M. The position accounts for 2.05% of the portfolio, ranked #13.

Stempoint Capital first reported a position in ROIV in Q4 2023 and has held it in 10 quarters since. The position peaked at $63.5M in Q3 2025. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Stempoint Capital held 385,800 shares of Roivant Sciences worth $10.7M as of Q1 2026.
  • Stempoint Capital sold 580,898 Roivant Sciences shares in Q1 2026, an estimated $14.9M.
  • Roivant Sciences made up 2.05% of Stempoint Capital's portfolio in Q1 2026, its #13 holding.
  • Stempoint Capital first reported a position in Roivant Sciences in Q4 2023 and has held it in 10 quarters since.
  • Stempoint Capital's Roivant Sciences position peaked at $63.5M in Q3 2025.
  • 439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.